This percentage may increase by screening nephrolithiasis patients for mutations in USP2 or in clock genes controlling its expression such as ARNTL (BMAL1) and CLOCK and their binding sites in the promoter of USP2. This evidence concerns the gene BMAL1 and nephrolithiasis.